Outlier in a BE study [Outliers]

posted by Helmut Homepage – Vienna, Austria, 2014-01-16 15:54 (3840 d 23:39 ago) – Posting: # 12181
Views: 9,827

Hi Kumar,

❝ FDA does not encourage redosing to handle outliers subjects incase of non-replicate design study…


❝ … wherein you may carry out redosing incase of replicate design.

I don’t think so – at least in a fully replicated design (see this post). In a partial replicate – if the “outlier” occurred after T – I would not perform a re-dosing study without contacting FDA OGD’s review stuff beforehand.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
 Admin contact
23,117 posts in 4,859 threads, 1,647 registered users;
44 visitors (0 registered, 44 guests [including 10 identified bots]).
Forum time: 16:33 CEST (Europe/Vienna)

You can’t really say “similar” if it’s the same again you want.
“Similar” means something different.    Anthony Burgess

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz